



PRESS RELEASE

Sven Zimmermann joins PregLem as CFO

Geneva, Switzerland, 13 May 2008 – PregLem SA, a Swiss biopharmaceutical company specialized in reproductive medicine, is pleased to announce that Sven Zimmermann, a well-known biotech analyst at UBS Investment Bank, will become its new Chief Financial Officer (CFO) as of 1 June 2008. Eric Rolin, a co-founder of PregLem who has held the position of CFO until now, will continue to be active in the company and participate in its development.

Dr. Zimmermann, a German national, has been with UBS AG since 2001. He started as a buy-side global pharma/biotech analyst at UBS Wealth Management Research, based in Zurich. In 2004 he moved to UBS Investment Bank as a sell-side European biotech analyst based in Geneva and London, where he expanded the UBS European biotech sphere. Dr. Zimmermann obtained a PhD in molecular biology from the University of Zurich and spent several years as a researcher in the fields of oncology, diabetes and virology, with publications in top scientific journals. He studied for an executive MBA from the Graduate School of Business Administration (GSBA) in Zurich and the State University at Albany, New York.

Dr. Ernest Loumaye, CEO of PregLem, commented, “We are delighted to have Sven Zimmermann reinforce our management team in Geneva. His extensive experience as a pharma and biotech analyst will be very valuable as our young and fast-growing company advances several innovative compounds through clinical development. We are pleased that Eric Rolin, with whom I have worked closely in building up the company, will continue to play an important strategic role.”

About PregLem

PregLem SA is a Swiss specialty biopharmaceutical company focused on the development and commercialization of innovative compounds for the treatment of major benign gynecological conditions as well as infertility. PregLem currently has four products in clinical and pre-clinical development. Its most advanced product, PGL4001, has already successfully completed Phase II clinical trials for the treatment of uterine myoma. In 2007, PregLem raised CHF 68 million from leading life science investors in Series A and B funding rounds. The company obtained SME status from the European Medicines Agency (EMA) in November 2007. PregLem was founded in Geneva in 2006 by Ernest Loumaye and Eric Rolin.

More information is available at www.preglem.com.



For further information, please contact:

Solveig Hole
PregLem CEO office
Tel: +41 22 884 03 40
Email: solveig.hole@preglem.com

Dr. Jonathan Leighton
Leighton Communications
Tel: +41 76 559 67 88
Email: jonl@sunrise.ch